On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers.

Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine / Roberto, Michela; Romiti, Adriana; Botticelli, Andrea; Mazzuca, Federica; Lionetto, Luana; Gentile, Giovanna; Paris, Ida; Falcone, Rosa; Bassanelli, Maria; DI PIETRO, FRANCESCA ROMANA; Onesti, CONCETTA ELISA; Anselmi, Elisabetta; Macrini, Serena; Simmaco, Maurizio; Marchetti, Paolo. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - STAMPA. - 73:2(2017), pp. 157-164. [10.1007/s00228-016-2160-8]

Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine

ROBERTO, MICHELA;ROMITI, ADRIANA;BOTTICELLI, ANDREA;MAZZUCA, FEDERICA;GENTILE, Giovanna;FALCONE, ROSA;BASSANELLI, MARIA;DI PIETRO, FRANCESCA ROMANA;ONESTI, CONCETTA ELISA;ANSELMI, ELISABETTA;MACRINI, SERENA;SIMMACO, Maurizio;MARCHETTI, PAOLO
2017

Abstract

On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers.
2017
adjuvant capecitabine; gene polymorphisms; oral fluoropyrimidines; personalized medicine; predictive biomarkers; toxicity
01 Pubblicazione su rivista::01a Articolo in rivista
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine / Roberto, Michela; Romiti, Adriana; Botticelli, Andrea; Mazzuca, Federica; Lionetto, Luana; Gentile, Giovanna; Paris, Ida; Falcone, Rosa; Bassanelli, Maria; DI PIETRO, FRANCESCA ROMANA; Onesti, CONCETTA ELISA; Anselmi, Elisabetta; Macrini, Serena; Simmaco, Maurizio; Marchetti, Paolo. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - STAMPA. - 73:2(2017), pp. 157-164. [10.1007/s00228-016-2160-8]
File allegati a questo prodotto
File Dimensione Formato  
Roberto_Evaluation_2017.pdf

solo utenti autorizzati

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 738.75 kB
Formato Adobe PDF
738.75 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/905033
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact